WPI 2285 (Propafenone Hydrochloride Extended-Release 225 mg)
Pill with imprint WPI 2285 is White, Capsule-shape and has been identified as Propafenone Hydrochloride Extended-Release 225 mg. It is supplied by Actavis Pharma, Inc..
Propafenone is used in the treatment of atrial fibrillation; atrial flutter; wolff-parkinson-white syndrome; ventricular tachycardia and belongs to the drug class group I antiarrhythmics. Risk cannot be ruled out during pregnancy. Propafenone 225 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for WPI 2285
More about propafenone
- Propafenone Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 51 Reviews
- Drug class: group I antiarrhythmics
- FDA Alerts (1)
- Propafenone Tablets
- Propafenone Sustained-Release Capsules
- Propafenone (Advanced Reading)
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.